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A B S T R A C T  
 
Introduction: Hypokalemia is common disorder characterized by low plasma 
potassium levels (<3.5 mEq / L). Hypokalemia can be caused by genetic disorders. 
Bartter syndrome and Gitelman syndrome are rare genetic disorders that cause 
damage to the tubular kidneys. The cause of hypokalemia must be determined by 
analyzing the diagnosis algorithm of hypokalemia. 
Case Illustration: A 27-year-old woman was brought to the emergency room with 
complaints of weakness in both legs since 1 day ago. Obtained a history of chronic 
hypokalemia since 5 years ago. No history of thyroid disease, and never taking 
diuretic drugs. The patient is calm. Vital signs: BP: 110/60, regular pulse 88x/minute, 
temperature: 36.7°C, respiratory rate 14x/minute, oxygen saturation 99% in room air. 
ECG showed Normal sinus rhythm with normal T wave. Laboratory findings showed 
severe hypokalemia with plasma potassium 1.7 mEq/L, increased urine potassium 
(71.1 mmol/24 hours), increased urine sodium 306 mmol/24 hours, and increased 
urine chloride (342 mmol/24 hours), plasma magnesium levels were normal (1.91 
mg/dL). KCl infusion was given to correct electrolyte imbalance condition. 
Discussion: Several examinations must be performed to confirm the cause of 
hypokalemia condition. The diagnosis of this patient was suspected to lead to Bartter 
syndrome and Gitelman syndrome, because there was an increase in urinary 
potassium excretion, normotensive conditions, no suspicion of metabolic acidosis, 
and no symptoms of nausea and vomiting and no history of diuretic drugs usage. 
 
Keywords: Hypokalemia, Bartter syndrome, Gitelman syndrome 
I N T R O D U C T I O N 
Hypokalemia is a common disorder 
characterized by low plasma potassium levels 
(<3.5 mEq/L).(1) Hypokalemia can be caused by 
abnormal potassium loss (drug use, 
gastrointestinal loss, kidney loss), transcellular 
changes (use of insulin drugs, beta agonists, 
alkalosis, thyrotoxicosis, etc.), inadequate 
intake (anorexia, dementia), as well as pseudo 
hypokalemia (delayed examination of samples, 
and significant leukocytosis (>75,000 
cells/mm3).(2) Hypokalemia can also be caused 
by genetic disorders. Bartter syndrome and 
Gitelman syndrome are congenital disorders 
caused by mutations of several genes that are 
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inherited autosomal recessive and impact on 
kidney tubular damage related to sodium, 
potassium, and chloride regulation. The 
incidence of Bartter syndrome is quite rare, 
about 1: 1,000,000 of the total population.(3) 
while Gitelman syndrome occurs in 
approximately 1: 40.000 in Caucasian 
individuals.(4) 
 The main symptom of Bartter 
syndrome and Gitelman syndrome is chronic 
hypokalemia, which can cause headaches, 
dizziness, constipation, cramps, and muscle 
weakness.(5) In some individuals, Bartter 
syndrome and Gitelman syndrome can result in 
a significant electrolyte imbalance. This 
condition can cause irregular heartbeats 
(arrhythmias) which can lead to sudden cardiac 
arrest.(6) Hypokalemia conditions need to be 
found the underlying cause, so that the therapy 
can be optimal. It can be determined by 
analyzing the diagnosis algorithm of 
hypokalemia. Several examinations must be 
performed to confirm the diagnosis.  In this case 
report, we will discuss a case of chronic 
hypokalemia on a young female patient with 
suspected renal tubulopathy, with a focus on 
the algorithm that can be taken in establishing 
the cause of the diagnosis of hypokalemia.  
C A S E  I L L U S T R A T I O N  
A 27-year-old woman was brought to 
the Emergency Room at the University of 
Muhammadiyah Malang Hospital with 
complaints of weakness in both legs since 1 day 
ago. The weakness is felt so severe that the 
patient cannot walk. This condition does not 
improve with rest. In addition, the patient also 
complained of nausea, and had 
constipationsince 2 days ago. The patient had a 
history of recurrent hypokalemia since 5 years 
ago. Hospitalization episodes are quite 
frequent. Almost once a month patient is 
hospitalized for hypokalemic conditions with 
unknown cause. There was no history of thyroid 
disease, and the patient had never taken 
diuretic drugs. On physical examination, the 
patient is in a calm condition. Vital signs were: 
BP: 110/60, pulse rate is regular 88x/minute, 
body temperature: 36.7°C, respiratory rate 
14x/minute and oxygen saturation 99% on 
room air. The results of the EKG show a normal 
sinus rhythm with a heart rate of 88x/minute, 
regular, and normal T waves. The results of 
laboratory tests showed that complete blood 
count was within normal limits, while on 
electrolyte examination, the plasma potassium 
level was quite low (1.7 mEq/L). Previous 
history, in 2016 the patient had an ultrasound, 
MRI, and urine electrolyte examination. From 
the results of ultrasound examination, it was 
found that focal ectasis was found on the right 
kidney superior and inferior pole, and complex 
cyst on the superior pole of the left kidney. MRI 
results did not show mass or enhancement in 
the right and left adrenal glands. Complex cysts 
found on the superior pole of the left kidney 
according to Bosniak IIF criteria. Focal ectasis 
found on calyx major inferior pole on right 
kidney, and simple cyst on the superior pole on 
right kidney according to Bosniak I criteria. 
From the results of urine electrolyte 
examination, the value of urine sodium was 306 
(40-220) mmol/24hours, urine potassium 71.1 
(25-125) mmol/24hours, and urine chloride 342 
(110-250) mmol/24hours. Plasma magnesium 
levels have also been checked and the results 
obtained are 1.91 (1,58-2,55) mg/dL. This 
patient has excessive urine sodium and urine 
potassium excretion, while magnesium levels is 
within normal limit. The patient was diagnosed 
with chronic hypokalemia with suspected 
tubular abnormalities in the kidney leading to 
Bartter Syndrome and Gitelman Syndrome. 
After consultation with an internist, the patient 
received KCl 50mEq infusion therapy within 12 
hours and then repeated up to 3 times. For oral 
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therapy, the patient got Kalium Sustained-
Release (KSR) tablet therapy 3x600mg a day. In 
addition, patients also received 1x100mg 
spironolactone. Rechecking the serum 
electrolyte was done after the KCl infusion 
therapy was finished. The patient was 
discharged in a stable condition and had no 
complaints with the results of plasma 
potassium 3,7mEq / L. 
D I S C U S S I O N  
Hypokalemia is a condition that must be 
treated immediately. The appearance of 
warning signs at hypokalemia requires 
immediate treatment. Conditions that include a 
warning sign are severe hypokalemia 
(<2.5meq/L), hypokalemia with sudden onset, 
palpitations, muscle weakness, changes in ECG 
waves, or the patient has a history of heart 
disease or underlying hepatic cirrhosis.(2) In this 
case, a 27-year-old female patient experienced 
several warning signs such as muscle weakness 
in both lower extremities which occurred 
suddenly and got worse since 1 day ago and low 
Potassium level (1,7mEq/L). Gastrointestinal 
causes of hypokalemia such as low intake, 
nausea, vomiting, and diarrhea can be 
excluded. History of drugs that can affect 
potassium levels such as insulin use, thyroid 
hormone boosters, beta adrenergic, and 
diuretics can also be excluded. From the past 
history and physical examination, the patient 
was also not hyperthyroid and did not show any 
metabolic acidosis. The condition of 
hypokalemia in this patient is suspected to be 
due to tubulopathy in the kidneys. 
Investigations such as an electrocardiogram 
are useful for checking for arrhythmias or other 
electrolyte abnormalities.
Figure 1. Diagnosis Algorithm of Hypokalemia(6)
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Laboratory tests showed a very low 
potassium level (1.7 mEq/L). The cause of the 
hypokalemia in this patient was determined 
using urine electrolytes examination. A urine 
potassium value of more than 30 indicates a 
leak of potassium from the urine. If urine 
potassium value is high, it can be evaluated by 
the patient's blood pressure. In hypertensive 
patients, hyperaldosteronism is suspected, 
whereas in normotensive conditions the 
decreased ability of the kidneys to retain 
potassium can be divided according to the 
accompanying acid-base disorders. Metabolic 
acidosis is usually caused by diabetic 
ketoacidosis and renal tubular acidosis. 
Whereas in conditions of metabolic alkalosis, it 
can be caused by severe vomiting, use of 
diuretics, or Bartter and Gitelmansyndrome.(7) 
Blood gas analysis was not examined in this 
patient so that the patient's acid-base status 
cannot be determined certainty. However, 
from the results of the anamnesis and physical 
examination, she did not show any symptoms 
leading to metabolic acidosis. The diagnosis is 
suspected to Bartter syndrome and Gitelman 
syndrome, because the patient found 
increased excretion of potassium through 
urine, normotensive conditions, no suspicion 
of metabolic acidosis, and no symptoms of 
nausea and vomiting and no history of using 
diuretic drugs. The difference between Bartter 
syndrome and Gitelman syndrome is as 
follows:
Table 1. Differences between Bartter and GitelmanSyndrome(4,6,8) 
Featured Bartter Syndrome Gitelman Syndrome 
Pathophysiology 
 
Genetic tubular defects (SLC12A1, KCNJ1, 
CLCNKA, or BSND genes) in Loop of Henle 
sodium chloride transport that produce a 
clinical disorder. Appears similar to that 
seen with chronic ingestion of a loop 
diuretic 
Genetic tubular defects 
(SLC12A3 or CLCNKB genes) in Distal 
tubule sodium chloride transport produce 
a clinical disorder. Appears similar to that 
seen with chronic ingestion of a thiazide 
diuretic 
Location Ascending thick limb of the loop of Henle Distal convoluted tubule 
Urinary calcium excretion Normal or increased, commonly with 
nephrocalcinosis 
Decreased 
Serum magnesium  Normal or decreased Decreased, sometimes greatly 
Renal prostaglandin E2 
production 
Increased Normal 
Usual age at presentation Before birth to early childhood, often with 
intellectual disability and growth 
disturbance 
Late childhood to adulthood 
Neuromuscular symptoms Uncommon or mild Common 
From the table above, the point that 
leads to Bartter syndromein this patient is 
normal magnesium level. The points that lead 
to Gitelman syndrome are the usual age at 
presentation that usually occurs in adult 
patients and commonly develops 
neuromuscular disorders such as muscle 
weakness, spasms, and cramps. The diagnosis 
that suitable for this patient is more likely leads 
to Gitelman Syndrome. To certainly distinguish 
these two syndromes, molecular genetic 
testing can be performed to detect mutations in 
specific genes.(6) We can perform molecular 
genetic testing such as SLC12A1, KCNJ1, 
CLCNKA, and BSND genesfor Bartter syndrome.  
Gitelman syndrome can be detected by 
performing molecular genetic test such as 
SLC12A3 or CLCNKB genes.(4,6) Currently, it is 
possible to make diagnosis of Barter and 
Gitelman in one patient. In Bartter syndrome 
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type III, there are similar characteristics with 
Gitelman syndrome. Some children with 
Bartter syndrome type III also present with 
Gitelman phenotype as CLC-NKB found in the 
distal convoluted tubule and in the connecting 
tubule.(8)In this case, molecular genetic 
examination was not examined due to limited 
facilities. 
Results of ultrasound examination, it 
was found that focal ectasis on the superior and 
inferior poles of the right kidney, as well as 
complex cysts on the superior and inferior pole 
of the left kidney. From the Abdominal MRI 
results, there was no mass or enhancement in 
the right and left adrenal glands, complex cysts 
found on the superior pole of the left kidney 
according to the Bosniak IIF criteria, Focal 
ectasis found on calyx major inferior pole on 
right kidney, and simple cyst on the superior 
pole on right kidney according to Bosniak I 
criteria. Chronic hypokalemia is known to 
induce renal cyst formation in some disease 
including primary aldosteronism, distal renal 
tubular acidosis, Liddle disease and apparent 
mineralocorticoid excess syndrome.(9) Renal 
cyst formation in Bartter syndrome and 
Gitelman syndrome rarely reported before. 
Although the precise mechanism underlying 
the development of renal cysts in our patient 
remains unclear, chronic hypokalemia may 
contribute to cyst development.(9) Bosniak 
classification can be used to predict the risk of 
cysts in the kidney to develop into malignancy. 
Bosniak I cysts are benign, while BosniakIIF 
cysts are likely to be benign, and very rarely 
develop into malignancy.(10) 
KCl infusion therapy was given at a dose 
of 50mEq in 500cc 0.9% NaCl, finished within 12 
hours, the administration was repeated up to 3 
times. For oral therapy, KSR 3x1 tablets a day 
and Spironolactone 1x100mg were given. 
Rechecking the serum electrolyte was done 
after the KCl infusion therapy was finished. This 
therapy is in accordance with the theory. In 
severe hypokalemic conditions (Potassium 
<2,5mEq / L) a maximum KCl can be given at a 
dose of 60mEq dissolved in 1000cc 0.9% NaCl at 
a speed below 10mEq/hour. Oral potassium 
replacement given at a dose of 40-60mEq can 
increase potassium levels by 1-1.5mEq/L.(7,11) 
Spironolactone is a specific aldosterone 
antagonist that binds competitively to the 
aldosterone-dependent sodium-potassium 
exchange site in the distal tubule. This can 
increase water excretion and hold potassium.(5) 
Bartter's syndrome and Gitelman syndrome are 
usually accompanied by 
hypomagnesemia.(6)The magnesium level in 
this patient is normal(1.91 mg/d), so it does not 
require additional therapy to correct 
magnesium levels. Currently, there is no 
definitive treatment for Bartter and Gitelman 
syndrome. The treatment is focused on fluid 
and electrolyte correction. Severity of 
symptoms (and associated complications) vary 
from person to person. People with Bartter and 
Gitelman syndrome must take medications 
consistently, as prescribed, throughout their 
lifetime. They also must be careful to maintain 
an adequate fluid and electrolyte balance.(6) 
C O N C L U S I O N 
Hypokalemia can be fatal and life 
threatening if not treated immediately. In 
addition, the cause of hypokalemia must also 
be known. Tubulopathic disorders of the 
kidneys such as Bartter Syndrome and 
Gitelman are very rare, but it is important to 
know so that the therapy given to patients can 
be optimal. 
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